Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Fine & Speciality Chemicals
Return to: PBR Home | Production & Manufacturing | Fine & Speciality Chemicals

Fine & Speciality Chemicals

Bayer plans to focus entirely on Life Science businesses Bayer intends in the future to focus entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a world-leading company in the field of human, animal and plant health.
Production & Manufacturing > Fine & Speciality Chemicals > News
CordenPharma agrees to purchase Peptisyntha from Solvay By PBR Staff Writer
International Chemical Investors Group (ICIG) and the Solvay Group have embarked on an agreement, whereby ICIG will purchase Belgium-based Peptisyntha SA, a custom manufacturer of peptides for pharmaceutical use.
Production & Manufacturing > Fine & Speciality Chemicals > News INVISTA, SilicoLife to develop new technologies for bio-derived processes By PBR Staff Writer
INVISTA and SilicoLife, a computational biology company, have collaborated to develop new technologies that facilitate bio-derived processes for the production of industrial chemicals.
Production & Manufacturing > Fine & Speciality Chemicals > News
See more Fine & Speciality Chemicals news

Latest Fine & Speciality Chemicals News and Insight

View all Fine & Speciality Chemicals news or find news targeted to your interests
Johnson Matthey Acquires Pharmaceutical Manufacturing Capacity in Scotland, UK
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland, U.K. The 109,000 sq. metre site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients utilising enhanced manufacturing capabilities.
Production & Manufacturing > Fine & Speciality Chemicals > Press Releases
Johnson Matthey Commissions New High Containment Manufacturing Capacity in Edinburgh, UK
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion and commissioning of new high containment facilities for potent product manufacture at its Edinburgh, UK site (Macfarlan Smith).
Production & Manufacturing > Fine & Speciality Chemicals > Press Releases
Johnson Matthey Rebrands its Fine Chemicals Division
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has today unveiled the distinctive new branding for its Fine Chemicals Division. The new brand brings together Johnson Matthey’s broad chiral and catalysis technologies, its world-leading opiates and narcotics capabilities, and global API development, life cycle management and manufacturing expertise.
Production & Manufacturing > Fine & Speciality Chemicals > Press Releases
Johnson Matthey Receives Two Pharmaceutical and Biotech CMO Leaderships Awards 2015
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has been recognised in the 2015 CMO Leadership Awards for the Reliability and Regulatory Track record of its Pharma Services to the Biotech Industry.
Production & Manufacturing > Fine & Speciality Chemicals > Press Releases
Johnson Matthey Acquires Pharmorphix
Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has acquired the Pharmorphix® solid form research business from Sigma-Aldrich. This acquisition brings world-leading material science capabilities to Johnson Matthey’s expanding European API and clinical supply services.
Production & Manufacturing > Fine & Speciality Chemicals > Press Releases
Novo Nordisk Pharmatech A/S - Insulin Human and Benzalkonium Chloride Products
Novo Nordisk Pharmatech A/S is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
High Containment
We are able to handle various levels of highly potent APIs in R&D, developmental manufacturing and full production settings. Our state-of-the-art facilities are equipped to carry out a wide range of chemical transformations, specialty separations and catalysis.
Production & Manufacturing > Fine & Speciality Chemicals > Products
Catalysis and Chiral Tech
We have unmatched expertise and a broad portfolio of heterogeneous, homogenous, chiral and biocatalytic technologies for customers in the pharmaceutical, fine chemical and agrochemical industries.
Production & Manufacturing > Fine & Speciality Chemicals > Products
View all Fine & Speciality Chemicals news or find news targeted to your interests